We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Earnings Estimates Moving Higher for DaVita HealthCare (DVA): Time to Buy?
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.
Analysts' growing optimism on the earnings prospects of this kidney dialysis provider is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For DaVita HealthCare, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
Current-Quarter Estimate Revisions
For the current quarter, the company is expected to earn $1.88 per share, which is a change of +18.99% from the year-ago reported number.
Over the last 30 days, two estimates have moved higher for DaVita HealthCare compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 10.58%.
Current-Year Estimate Revisions
For the full year, the company is expected to earn $8.97 per share, representing a year-over-year change of +5.9%.
In terms of estimate revisions, the trend for the current year also appears quite encouraging for DaVita HealthCare. Over the past month, three estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 9.11%.
Favorable Zacks Rank
The promising estimate revisions have helped DaVita HealthCare earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom Line
DaVita HealthCare shares have added 18.4% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Earnings Estimates Moving Higher for DaVita HealthCare (DVA): Time to Buy?
DaVita HealthCare (DVA - Free Report) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.
Analysts' growing optimism on the earnings prospects of this kidney dialysis provider is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For DaVita HealthCare, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
Current-Quarter Estimate Revisions
For the current quarter, the company is expected to earn $1.88 per share, which is a change of +18.99% from the year-ago reported number.
Over the last 30 days, two estimates have moved higher for DaVita HealthCare compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 10.58%.
Current-Year Estimate Revisions
For the full year, the company is expected to earn $8.97 per share, representing a year-over-year change of +5.9%.
In terms of estimate revisions, the trend for the current year also appears quite encouraging for DaVita HealthCare. Over the past month, three estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 9.11%.
Favorable Zacks Rank
The promising estimate revisions have helped DaVita HealthCare earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom Line
DaVita HealthCare shares have added 18.4% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.